HERON THERAPEUTICS INC (HRTX) competitors & alternatives
Health Care · NASDAQ
HERON THERAPEUTICS INC (HRTX)'s top competitors and alternatives — its most similar public companies — include Merck & Co. (MRK), PACIRA BIOSCIENCES INC (PCRX), AVANOS MEDICAL INC (AVNS), COLLEGIUM PHARMACEUTICAL INC (COLL), ALKERMES (ALKS), FENNEC PHARMACEUTICALS INC (FENC), VANDA PHARMACEUTICALS INC (VNDA), AMPHASTAR PHARMACEUTICALS INC (AMPH), Universal Health Services (UHS), INDIVIOR PHARMACEUTICALS INC (INDV), HCA Healthcare (HCA) and Baxter International (BAX). These are HERON THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top HRTX competitors & alternatives
-
Merck & Co.MRKHealth Care
Global pharmaceutical and vaccine leader with oncology, infectious disease, and animal health franchises, anchored by blockbuster immunotherapy Keytruda.
$127.47 (as of 2026-07-22) · market cap $315.3B
-
PACIRA BIOSCIENCES INCPCRXHealth Care
Pacira BioSciences is a non-opioid pain management company commercializing injectable, device, and gene therapy treatments for postsurgical and osteoarthritis…
$25.59 (as of 2026-07-22) · market cap $1.0B
-
AVANOS MEDICAL INCAVNSHealth Care
Avanos Medical delivers non-opioid pain management and specialized nutrition feeding devices to hospitals and home care providers, reducing opioid dependency…
$24.98 (as of 2026-07-22) · market cap $1.2B
-
COLLEGIUM PHARMACEUTICAL INCCOLLHealth Care
A specialty pharma company building a diversified pain and ADHD portfolio through branded products and acquisitions, though facing material generic headwinds…
$34.72 (as of 2026-07-22) · market cap $1.1B
-
ALKERMESALKSHealth Care
Alkermes is a neuroscience-focused biopharmaceutical company commercializing branded therapies for schizophrenia, bipolar disorder, narcolepsy, and substance…
$52.58 (as of 2026-07-22) · market cap $8.8B
-
FENNEC PHARMACEUTICALS INCFENCHealth Care
Commercial-stage biopharma company bringing PEDMARK, the first and only approved drug to prevent cisplatin-induced ototoxicity in pediatric cancer patients, to…
$10.32 (as of 2026-07-22) · market cap $359M
-
VANDA PHARMACEUTICALS INCVNDAHealth Care
Niche biopharmaceutical company commercializing approved therapies for psychiatry, sleep disorders, and multiple sclerosis while pursuing pipeline expansion in…
$5.35 (as of 2026-07-22) · market cap $329M
-
AMPHASTAR PHARMACEUTICALS INCAMPHHealth Care
Amphastar manufactures technically complex generic and proprietary injectable, inhalation, and intranasal drugs with high barriers to entry, leveraging…
$19.30 (as of 2026-07-22) · market cap $864M
-
Universal Health ServicesUHSHealth Care
Large diversified hospital operator running 375 acute care and behavioral health inpatient facilities across the US, UK, and Puerto Rico, with 42% of revenues…
$149.34 (as of 2026-07-22) · market cap $9.1B
-
INDIVIOR PHARMACEUTICALS INCINDVHealth Care
Indivior is a specialty pharmaceutical company dedicated to developing and marketing treatments for substance use disorders and mental health conditions,…
$40.45 (as of 2026-07-22) · market cap $4.9B
-
HCA HealthcareHCAHealth Care
Leading U.S.
$371.87 (as of 2026-07-22) · market cap $82.7B
-
Baxter InternationalBAXHealth Care
A diversified healthcare company producing sterile IV solutions, infusion systems, parenteral nutrition, inhaled anesthetics, surgical sealants, smart beds,…
$21.74 (as of 2026-07-22) · market cap $11.5B
Not quite? Describe exactly what you want →
Peers are HERON THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: HERON THERAPEUTICS INC (HRTX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.